GlassScriptPhysician profile
Geoffrey Lee
NPI 1578528873
$15,018.27
in general payments reported to CMS, 2019-2025
28 companies · $953 in 2025
The $953 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,086 · 2020: $1,397 · 2021: $986 · 2022: $1,077 · 2023: $754 · 2024: $765 · 2025: $953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,216 · Education: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,216.12 |
| Education | $256.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $10,505.74 | 2019-2025 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $604.98 | 2019-2025 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $500.47 | 2020-2025 | Acthar, Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $479.08 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $297.89 | 2019-2024 | Velphoro, Korsuva |
| Otsuka America Pharmaceutical, INC. | $268.53 | 2021-2025 | Jynarque |
| Mallinckrodt Enterprises LLC | $267.22 | 2019 | |
| Vifor Pharma, INC. | $239.74 | 2019-2024 | Veltassa |
| Horizon Therapeutics Plc | $221.40 | 2019-2023 | Krystexxa |
| Amgen INC. | $196.23 | 2019-2025 | Tavneos, Krystexxa |
| Akebia Therapeutics INC | $184.93 | 2019-2025 | Vafseo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.31 | 2022-2025 | Jardiance |
| Glaxosmithkline, LLC. | $133.63 | 2021-2024 | Jesduvroq, Benlysta |
| Aurinia Pharma U.S., INC. | $133.02 | 2022-2024 | Lupkynis |
| Calliditas Therapeutics US INC. | $131.26 | 2023-2025 | Tarpeyo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $108.79 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $108.44 | 2022-2024 | Purified Cortrophin Gel |
| Travere Therapeutics, INC. | $97.29 | 2023-2025 | |
| Lilly USA, LLC | $85.73 | 2024-2025 | Jardiance |
| Ardelyx, INC. | $65.97 | 2024-2025 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $56.02 | 2019-2025 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $48.07 | 2020-2024 | Gattex |
| Alnylam Pharmaceuticals INC. | $37.52 | 2023-2025 | Givlaari |
| Nxstage Medical, INC. | $32.33 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $23.70 | 2021 | |
| Janssen Pharmaceuticals, INC | $20.00 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.27 | 2025 | |
| Scpharmaceuticals INC. | $16.71 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geoffrey Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.